Find, compare & contact
Riferminogene pecaplasmid
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Riferminogene pecaplasmid API 1001859-46-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Riferminogene pecaplasmid. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Riferminogene pecaplasmid
- Synonyms:
- Non-viral fibroblast growth factor 1 , NV1FGF , Riferminogene pecaplasmid
- Cas Number:
- 1001859-46-6
- DrugBank number:
- DB06394
- Unique Ingredient Identifier:
- 3G30P7ME1J
General Description:
Riferminogene pecaplasmid, identified by CAS number 1001859-46-6, is a notable compound with significant therapeutic applications. Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in amputation (limb) and peripheral vascular disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Riferminogene pecaplasmid functions by: NV1FGF is a novel pCOR DNA plasmid–based gene delivery system for local expression of FGF-1. The pCOR plasmid backbone has several features that increase biosafety. These attributes include replication in only a narrow host range of laboratory, but not wild type, Escherichia coli strains, absence of an antibiotic-resistance gene, and lack of the potentially immunostimulatory sequence motifs found in ColE1 plasmids. Preclinical studies of intramuscular administration of NV1FGF have demonstrated that local expression of FGF-1 persists for several weeks. The angiogenic effect of NV1FGF was confirmed in the more severe animal model. The administration of NV1FGF in the hypercholesterolemic hamster model of hindlimb ischemia significantly enhanced the formation of large conductance vessels as well as small resistance arteries in ischemia-injured muscles. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Riferminogene pecaplasmid belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Riferminogene pecaplasmid is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
